Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. Development was discontinued due to concerns over hepatotoxicity observed in animal studies. Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Cyproheptadine | The therapeutic efficacy of Alaproclate can be decreased when used in combination with Cyproheptadine. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Desmopressin. |
| Ioflupane I-123 | Alaproclate may decrease effectiveness of Ioflupane I-123 as a diagnostic agent. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Alaproclate. |
| Metyrosine | The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Alaproclate. |
| Pimozide | The risk or severity of QTc prolongation can be increased when Alaproclate is combined with Pimozide. |
| Buprenorphine | Alaproclate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alaproclate. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Alaproclate. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Alaproclate. |
| Hydrocodone | Alaproclate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Alaproclate. |
| Magnesium sulfate | The therapeutic efficacy of Alaproclate can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Alaproclate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alaproclate. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Alaproclate. |
| Orphenadrine | Alaproclate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Alaproclate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Alaproclate. |
| Pramipexole | Alaproclate may increase the sedative activities of Pramipexole. |
| Ropinirole | Alaproclate may increase the sedative activities of Ropinirole. |
| Rotigotine | Alaproclate may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Alaproclate. |
| Sodium oxybate | Alaproclate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Alaproclate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Alaproclate. |
| Thalidomide | Alaproclate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Alaproclate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Alaproclate. |
| Tedizolid phosphate | The risk or severity of serotonin syndrome can be increased when Tedizolid phosphate is combined with Alaproclate. |
| Mirtazapine | Alaproclate may increase the serotonergic activities of Mirtazapine. |
| Morphine | The risk or severity of serotonin syndrome can be increased when Morphine is combined with Alaproclate. |
| Codeine | The risk or severity of serotonin syndrome can be increased when Codeine is combined with Alaproclate. |
| Hydromorphone | The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Alaproclate. |
| Meperidine | The risk or severity of serotonin syndrome can be increased when Meperidine is combined with Alaproclate. |
| Oxycodone | The risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Alaproclate. |
| Butorphanol | The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Alaproclate. |
| Dextropropoxyphene | The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Alaproclate. |
| Pentazocine | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Alaproclate. |
| Sufentanil | The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Alaproclate. |
| Alfentanil | The risk or severity of serotonin syndrome can be increased when Alfentanil is combined with Alaproclate. |
| Fentanyl | The risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Alaproclate. |
| Nalbuphine | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Alaproclate. |
| Levorphanol | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Alaproclate. |
| Remifentanil | The risk or severity of serotonin syndrome can be increased when Remifentanil is combined with Alaproclate. |
| Diphenoxylate | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Alaproclate. |
| Oxymorphone | The risk or severity of serotonin syndrome can be increased when Oxymorphone is combined with Alaproclate. |
| Dezocine | The risk or severity of serotonin syndrome can be increased when Dezocine is combined with Alaproclate. |
| Levacetylmethadol | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Alaproclate. |
| Methadyl acetate | The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Alaproclate. |
| Dihydroetorphine | The risk or severity of serotonin syndrome can be increased when Dihydroetorphine is combined with Alaproclate. |
| Diamorphine | The risk or severity of serotonin syndrome can be increased when Diamorphine is combined with Alaproclate. |
| Ethylmorphine | The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Alaproclate. |
| Etorphine | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Alaproclate. |
| Dextromoramide | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Alaproclate. |
| Desomorphine | The risk or severity of serotonin syndrome can be increased when Desomorphine is combined with Alaproclate. |
| Carfentanil | The risk or severity of serotonin syndrome can be increased when Carfentanil is combined with Alaproclate. |
| Dihydrocodeine | The risk or severity of serotonin syndrome can be increased when Dihydrocodeine is combined with Alaproclate. |
| Alphacetylmethadol | The risk or severity of serotonin syndrome can be increased when Alphacetylmethadol is combined with Alaproclate. |
| Dihydromorphine | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Alaproclate. |
| Ketobemidone | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Alaproclate. |
| DPDPE | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Alaproclate. |
| Lofentanil | The risk or severity of serotonin syndrome can be increased when Lofentanil is combined with Alaproclate. |
| Opium | The risk or severity of serotonin syndrome can be increased when Opium is combined with Alaproclate. |
| Normethadone | The risk or severity of serotonin syndrome can be increased when Normethadone is combined with Alaproclate. |
| Piritramide | The risk or severity of serotonin syndrome can be increased when Piritramide is combined with Alaproclate. |
| Alphaprodine | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Alaproclate. |
| Meptazinol | The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Alaproclate. |
| Phenoperidine | The risk or severity of serotonin syndrome can be increased when Phenoperidine is combined with Alaproclate. |
| Phenazocine | The risk or severity of serotonin syndrome can be increased when Phenazocine is combined with Alaproclate. |
| Tilidine | The risk or severity of serotonin syndrome can be increased when Tilidine is combined with Alaproclate. |
| Carfentanil, C-11 | The risk or severity of serotonin syndrome can be increased when Carfentanil, C-11 is combined with Alaproclate. |
| Naltrexone | The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Alaproclate. |
| Bezitramide | The risk or severity of serotonin syndrome can be increased when Bezitramide is combined with Alaproclate. |
| Eluxadoline | The risk or severity of serotonin syndrome can be increased when Eluxadoline is combined with Alaproclate. |
| Nicomorphine | The risk or severity of serotonin syndrome can be increased when Nicomorphine is combined with Alaproclate. |
| Benzhydrocodone | The risk or severity of serotonin syndrome can be increased when Benzhydrocodone is combined with Alaproclate. |
| Naloxegol | The risk or severity of serotonin syndrome can be increased when Naloxegol is combined with Alaproclate. |
| Iobenguane | Alaproclate may decrease effectiveness of Iobenguane as a diagnostic agent. |
| Methyclothiazide | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Methyclothiazide. |
| Chlorthalidone | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Chlorthalidone. |
| Bendroflumethiazide | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Bendroflumethiazide. |
| Metolazone | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Metolazone. |
| Benzthiazide | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Benzthiazide. |
| Hydroflumethiazide | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Hydroflumethiazide. |
| Indapamide | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Indapamide. |
| Chlorothiazide | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Chlorothiazide. |
| Hydrochlorothiazide | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Hydrochlorothiazide. |
| Trichlormethiazide | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Trichlormethiazide. |
| Polythiazide | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Polythiazide. |
| Quinethazone | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Quinethazone. |
| Cyclopenthiazide | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Cyclopenthiazide. |
| Epitizide | The risk or severity of hyponatremia can be increased when Alaproclate is combined with Epitizide. |
| Ethanol | Alaproclate may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Alaproclate may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Alaproclate. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Botulinum toxin type B is combined with Alaproclate. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alaproclate. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Alaproclate. |
| Ethchlorvynol | The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alaproclate. |